
Tahamtan Ahmadi built his career in the hard middle of biotechnology - where a scientific idea must survive evidence, regulation, and scale. At Genmab, his remit now stretches from discovery to medicine, and his public philosophy keeps returning to curiosity, collaboration, and patient impact.
A Danish antibody specialist turned one licensed molecule into a multibillion-dollar royalty engine. Now Genmab is spending that advantage on a harder act: becoming the company that carries more of its own cancer medicines from lab bench to patient.